The effects of nadolol on various cardiac tissues in normoxia, and on atrial muscle in simulated ischaemia
- PMID: 6129144
- DOI: 10.1016/0014-2999(82)90247-3
The effects of nadolol on various cardiac tissues in normoxia, and on atrial muscle in simulated ischaemia
Abstract
Nadolol, a non-selective beta-blocker with a long duration of action, reportedly is devoid of membrane stabilizing action. Since such action is augmented by ischaemic conditions, it was of interest to investigate whether, in simulated ischaemia, a direct membrane effect of nadolol might be revealed. We have confirmed that in normoxia nadolol had no effects on intracellulary recorded potentials in isolated rabbit atrial or ventricular muscle at a concentration of 4.84 microM, but significantly reduced action potential amplitude and maximum rate of depolarisation at 14.5 microM. In Purkinje cells a small reduction of action potential amplitude was produced by 1.61 microM nadolol, but the effect was not increased by nadolol 4.84 microM. There were no drug-induced changes in action potential duration (APD), spontaneous frequency, conduction velocity, contractions, electrical threshold, effective refractory period or the maximum frequency at which a stimulus could be followed. Nadolol 14.5 microM did not reduce the positive inotropic effect of increasing extracellular calcium concentrations. Nadolol was 25 times less potent than procaine as a local anaesthetic on desheathed frog nerve. In a solution simulating ischaemia (8 mM KCl, 10 mM NaHCO3, gassed with 20% O2, pH 7.0) nadolol had a significant class 1 action on atrial muscle, however, even at 4.84 microM and reduced the shortening of APD caused by the solution. It is concluded that nadolol has no class 1, 3 or 4 antiarrhythmic activity in normoxia, but could have an additional protective effect in ischaemic myocardium against the arrhythmogenic factor of shortened APD.
Similar articles
-
Direct and beta adrenergic blocking actions of nadolol (SQ 11725) on electrophysiologic properties of isolated canine myocardium.J Pharmacol Exp Ther. 1977 Sep;202(3):702-10. J Pharmacol Exp Ther. 1977. PMID: 19621
-
Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia.Br J Pharmacol. 1982 Mar;75(3):469-78. doi: 10.1111/j.1476-5381.1982.tb09163.x. Br J Pharmacol. 1982. PMID: 7066601 Free PMC article.
-
Electrophysiological effects of labetolol on rabbit atrial, ventricular and Purkinje cells, in normoxia and hypoxia.Cardiovasc Res. 1982 May;16(5):233-9. doi: 10.1093/cvr/16.5.233. Cardiovasc Res. 1982. PMID: 7105090
-
Investigations to characterize a new anti-arrhythmic drug, ORG 6001 including a simple test for calcium antagonism.Br J Pharmacol. 1976 Jun;57(2):251-62. doi: 10.1111/j.1476-5381.1976.tb07475.x. Br J Pharmacol. 1976. PMID: 7336 Free PMC article.
-
Electropharmacological effects of berberine on canine cardiac Purkinje fibres and ventricular muscle and atrial muscle of the rabbit.Br J Pharmacol. 1993 Feb;108(2):534-7. doi: 10.1111/j.1476-5381.1993.tb12836.x. Br J Pharmacol. 1993. PMID: 8448600 Free PMC article.
Cited by
-
Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.CNS Drugs. 2004;18(11):687-703. doi: 10.2165/00023210-200418110-00001. CNS Drugs. 2004. PMID: 15330685 Review.
-
Effects of bucumolol, nadolol and nifenalol on maximum upstroke velocity of action potential in guinea pig papillary muscles.Naunyn Schmiedebergs Arch Pharmacol. 1986 Mar;332(3):297-304. doi: 10.1007/BF00504871. Naunyn Schmiedebergs Arch Pharmacol. 1986. PMID: 2872598
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources